The companies said their vaccine helped prevent the return and spread of melanoma in a trial that involved more than 1,000 ...

Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak ...

A new vaccine is changing how doctors treat certain skin cancer patients, according to doctors in the ArkLaTex.

Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug ...

An Auckland woman who has spent months campaigning for cancer drug funding says the Petitions Select Committee’s response to ...

President Donald Trump’s announcement this week of White House aide Heidi Overton as his pick to lead the FDA gave the pharma ...

The personalised vaccine has succeeded in a final-stage melanoma trial. Here’s how it works, when it could become available ...

The experimental mRNA vaccine successfully cleared phase 3 clinical trials, the last step necessary before it can be approved ...

Novo Nordisk A/S stays a Buy as oral Wegovy surges and the GLP-1 pipeline strengthens; an attractive 2028 P/E suggests upside ...

The S&P 500 (SP500) closed in the green on Friday, as Treasury yields held mostly steady and Bitcoin (BTC-USD) saw sharp swings. Nasdaq (COMP:IND) fell 2% for the week, while the Dow (DJI) declined 1.

Moderna's cancer treatment could treat more than just Melanoma, though the stock's momentum is already stalling. Should you ...

After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the ...